CTT Pharma Gives Update On NSF Grant
CTT Pharmaceutical Holdings (OTC:CTTH) has advanced past the initial round in its application for a National Science Foundation (NSF) grant for its patented fast-dissolving nicotine strips. The company is now among a few thousand remaining applicants from an initial pool of over 12,000. CTT expects to receive a response by late April.
The company's technology aims to address a significant public health issue, as cited by WHO statistics showing tobacco kills over 8 million people annually worldwide. According to CDC data, cigarette smoking causes more than 480,000 deaths yearly in the United States, representing nearly 1 in 5 deaths.
CEO Ryan Khouri highlighted that CTT's advancement in the NSF application process demonstrates the potential value of their technology in the tobacco industry. The company notes that there are currently no fast-dissolving, low-dose nicotine strips available in the market.
CTT Pharmaceutical Holdings (OTC:CTTH) ha superato il primo turno nella sua domanda per un finanziamento della National Science Foundation (NSF) per le sue strisce di nicotina a dissoluzione rapida brevettate. L'azienda è ora tra i pochi migliaia di candidati rimasti da un pool iniziale di oltre 12.000. CTT si aspetta di ricevere una risposta entro la fine di aprile.
La tecnologia dell'azienda mira a affrontare un'importante questione di salute pubblica, come evidenziato dalle statistiche dell'OMS che mostrano come il tabacco uccida oltre 8 milioni di persone ogni anno in tutto il mondo. Secondo i dati dei CDC, il fumo di sigaretta causa più di 480.000 decessi ogni anno negli Stati Uniti, rappresentando quasi 1 morte su 5.
Il CEO Ryan Khouri ha sottolineato che il progresso di CTT nel processo di domanda NSF dimostra il potenziale valore della loro tecnologia nell'industria del tabacco. L'azienda osserva che attualmente non ci sono strisce di nicotina a dissoluzione rapida e a bassa dose disponibili sul mercato.
CTT Pharmaceutical Holdings (OTC:CTTH) ha avanzado más allá de la ronda inicial en su solicitud de una subvención de la National Science Foundation (NSF) para sus tiras de nicotina de disolución rápida patentadas. La compañía ahora está entre los pocos miles de solicitantes restantes de un grupo inicial de más de 12,000. CTT espera recibir una respuesta para finales de abril.
La tecnología de la compañía busca abordar un problema significativo de salud pública, según las estadísticas de la OMS que muestran que el tabaco mata a más de 8 millones de personas anualmente en todo el mundo. Según los datos de los CDC, el consumo de cigarrillos causa más de 480,000 muertes al año en los Estados Unidos, representando casi 1 de cada 5 muertes.
El CEO Ryan Khouri destacó que el avance de CTT en el proceso de solicitud de la NSF demuestra el potencial valor de su tecnología en la industria del tabaco. La compañía señala que actualmente no hay tiras de nicotina de disolución rápida y baja dosis disponibles en el mercado.
CTT Pharmaceutical Holdings (OTC:CTTH)는 특허받은 빠르게 용해되는 니코틴 스트립을 위한 National Science Foundation (NSF) 보조금 신청의 초기 단계를 통과했습니다. 이 회사는 12,000명 이상의 초기 지원자 중에서 남아 있는 몇 천 명의 지원자 중 하나가 되었습니다. CTT는 4월 말까지 응답을 받을 것으로 예상하고 있습니다.
회사의 기술은 WHO 통계에서 담배가 전 세계적으로 매년 800만 명 이상을 죽인다고 언급한 바와 같이, 중요한 공공 건강 문제를 해결하는 것을 목표로 하고 있습니다. CDC 데이터에 따르면, 미국에서 담배 흡연은 매년 48만 명 이상의 사망을 초래하며, 이는 거의 5명 중 1명에 해당합니다.
CEO 라이언 카우리(Ryan Khouri)는 CTT가 NSF 신청 과정에서 진전을 이룬 것은 담배 산업에서 그들의 기술의 잠재적 가치를 입증한다고 강조했습니다. 회사는 현재 시장에 빠르게 용해되는 저용량 니코틴 스트립이 없다고 언급하고 있습니다.
CTT Pharmaceutical Holdings (OTC:CTTH) a franchi la première étape de sa demande de subvention auprès de la National Science Foundation (NSF) pour ses bandes de nicotine à dissolution rapide brevetées. L'entreprise se trouve maintenant parmi les quelques milliers de candidats restants d'un pool initial de plus de 12 000. CTT s'attend à recevoir une réponse d'ici fin avril.
La technologie de l'entreprise vise à résoudre un problème de santé publique majeur, comme le montrent les statistiques de l'OMS indiquant que le tabac tue plus de 8 millions de personnes chaque année dans le monde. Selon les données des CDC, le tabagisme cause plus de 480 000 décès par an aux États-Unis, représentant presque 1 décès sur 5.
Le PDG Ryan Khouri a souligné que l'avancement de CTT dans le processus de demande de la NSF démontre la valeur potentielle de leur technologie dans l'industrie du tabac. L'entreprise note qu'il n'existe actuellement aucune bande de nicotine à dissolution rapide et à faible dose sur le marché.
CTT Pharmaceutical Holdings (OTC:CTTH) hat die erste Runde in seinem Antrag auf einen Zuschuss der National Science Foundation (NSF) für seine patentierten schnell auflösenden Nikotinstreifen erfolgreich durchlaufen. Das Unternehmen gehört nun zu den wenigen tausend verbliebenen Bewerbern aus einem ursprünglichen Pool von über 12.000. CTT erwartet, bis Ende April eine Antwort zu erhalten.
Die Technologie des Unternehmens zielt darauf ab, ein bedeutendes Problem der öffentlichen Gesundheit anzugehen, da die Statistiken der WHO zeigen, dass Tabak weltweit jährlich über 8 Millionen Menschen tötet. Laut CDC-Daten verursacht das Rauchen von Zigaretten in den Vereinigten Staaten jährlich mehr als 480.000 Todesfälle, was fast jedem fünften Todesfall entspricht.
CEO Ryan Khouri hob hervor, dass der Fortschritt von CTT im NSF-Antragsprozess den potenziellen Wert ihrer Technologie in der Tabakindustrie demonstriert. Das Unternehmen weist darauf hin, dass derzeit keine schnell auflösenden, niedrig dosierten Nikotinstreifen auf dem Markt erhältlich sind.
- Advanced to final rounds of NSF grant application from over 12,000 initial applicants
- Unique market position with no current competitors in fast-dissolving, low-dose nicotine strips
- Added experienced NSF grant specialist to team
- No guaranteed approval for NSF grant
- Product still in early development phase without market presence
TAMPA, FL / ACCESS Newswire / February 12, 2025 / CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) submitted a full proposal to the National Science Foundation(NSF) for our patented fast dissolving nicotine strips. The NSF grant program is highly competitive as it receives over 12,000 applicants annually from companies that have innovations that could help society. CTT successfully made it past the first round process and is among a few thousand remaining applicants. These remaining applicants have several deadlines over the course of the year to file a full proposal into the grant program. CTT is anticipating an answer in this program in late April. Acceptance into this program would give government backing to CTT Pharma and would allow for extensive research and testing to help lead to development of our technology.
The World Health Organization states, "The tobacco epidemic is one of the biggest public health threats the world has ever faced, killing over 8 million people a year around the world. More than 7 million of those deaths are results of direct tobacco use while 1.3 million are the result of non-smokers being exposed to second-hand smoke." Furthermore, the CDC says, "Cigarette smoking is the leading cause of preventable death in the United States. Cigarette smoking causes more than 480,000 deaths each year in the United States. This is nearly 1 in 5 deaths.
The CEO of CTT Pharma, Ryan Khouri stated, "To make it past the first round of applicants is a huge accomplishment by itself and shows that the NSF sees potential value for our technology within the tobacco industry. Currently there are no fast dissolving, low dose nicotine strips on the market, as most oral products stay in the mouth for an excessive amount of time. CTT also brought someone onto our team to help with this NSF Grant as they have a tremendous amount of experience with the NSF."
CTT will continue to update shareholders as more news becomes available.
CTT Pharma - 813-606-0060
SOURCE: CTT Pharmaceutical Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
When will CTT Pharmaceutical (CTTH) receive a response for their NSF grant application?
What makes CTT Pharmaceutical's (CTTH) nicotine strips unique in the market?
How many applicants did CTT Pharmaceutical (CTTH) compete against in the NSF grant program?
What is the potential market impact of CTT Pharmaceutical's (CTTH) nicotine strips?
